File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.pharmthera.2012.08.009
- Scopus: eid_2-s2.0-84867880208
- PMID: 22939883
- WOS: WOS:000311022900004
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: SIRT1 in metabolic syndrome: Where to target matters
Title | SIRT1 in metabolic syndrome: Where to target matters |
---|---|
Authors | |
Keywords | Aging Cardiovascular Diseases Metabolic Disorders Silent Information Regulator Sirtuin |
Issue Date | 2012 |
Publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/pharmthera |
Citation | Pharmacology And Therapeutics, 2012, v. 136 n. 3, p. 305-318 How to Cite? |
Abstract | Sirtuin 1 (SIRT1), the mammalian ortholog of yeast Sir2p, is a highly conserved NAD +-dependent protein deacetylase that has emerged as a key cardiometabolic regulator. During the past decade, Sir2p has been the focus of intense investigations and discussion because it regulates longevity in yeast, worms and flies. Although the extrapolation of data obtained from yeast Sir2p to mammalian SIRT1 cannot be automatic, animal studies provide convincing evidence that SIRT1 is a potent protector against aging-associated pathologies, in particular metabolic disorders and cardiovascular diseases. Indeed, many exciting connections exist between the protein deacetylation function of SIRT1 and its role in fundamental biological responses to various nutritional and environmental signals. As a result, pharmaceutical and nutriceutical interventions targeting SIRT1 are promising strategies to combat aging-associated diseases. The present review summarizes the recent progress in SIRT1 research with a particular focus on the specificities of this protein in individual tissues as they relate to cardiometabolic control. © 2012 Elsevier Inc. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/171452 |
ISSN | 2023 Impact Factor: 12.0 2023 SCImago Journal Rankings: 3.150 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, Y | en_US |
dc.contributor.author | Xu, C | en_US |
dc.contributor.author | Liang, Y | en_US |
dc.contributor.author | Vanhoutte, PM | en_US |
dc.date.accessioned | 2012-10-30T06:14:21Z | - |
dc.date.available | 2012-10-30T06:14:21Z | - |
dc.date.issued | 2012 | en_US |
dc.identifier.citation | Pharmacology And Therapeutics, 2012, v. 136 n. 3, p. 305-318 | en_US |
dc.identifier.issn | 0163-7258 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/171452 | - |
dc.description.abstract | Sirtuin 1 (SIRT1), the mammalian ortholog of yeast Sir2p, is a highly conserved NAD +-dependent protein deacetylase that has emerged as a key cardiometabolic regulator. During the past decade, Sir2p has been the focus of intense investigations and discussion because it regulates longevity in yeast, worms and flies. Although the extrapolation of data obtained from yeast Sir2p to mammalian SIRT1 cannot be automatic, animal studies provide convincing evidence that SIRT1 is a potent protector against aging-associated pathologies, in particular metabolic disorders and cardiovascular diseases. Indeed, many exciting connections exist between the protein deacetylation function of SIRT1 and its role in fundamental biological responses to various nutritional and environmental signals. As a result, pharmaceutical and nutriceutical interventions targeting SIRT1 are promising strategies to combat aging-associated diseases. The present review summarizes the recent progress in SIRT1 research with a particular focus on the specificities of this protein in individual tissues as they relate to cardiometabolic control. © 2012 Elsevier Inc. All rights reserved. | en_US |
dc.language | eng | en_US |
dc.publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/pharmthera | en_US |
dc.relation.ispartof | Pharmacology and Therapeutics | en_US |
dc.subject | Aging | en_US |
dc.subject | Cardiovascular Diseases | en_US |
dc.subject | Metabolic Disorders | en_US |
dc.subject | Silent Information Regulator | en_US |
dc.subject | Sirtuin | en_US |
dc.title | SIRT1 in metabolic syndrome: Where to target matters | en_US |
dc.type | Article | en_US |
dc.identifier.email | Wang, Y:yuwanghk@hku.hk | en_US |
dc.identifier.email | Vanhoutte, PM:vanhoutt@hku.hk | en_US |
dc.identifier.authority | Wang, Y=rp00239 | en_US |
dc.identifier.authority | Vanhoutte, PM=rp00238 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/j.pharmthera.2012.08.009 | en_US |
dc.identifier.pmid | 22939883 | - |
dc.identifier.scopus | eid_2-s2.0-84867880208 | en_US |
dc.identifier.hkuros | 219895 | - |
dc.identifier.isi | WOS:000311022900004 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Wang, Y=34973733700 | en_US |
dc.identifier.scopusauthorid | Xu, C=55245075900 | en_US |
dc.identifier.scopusauthorid | Liang, Y=55273172800 | en_US |
dc.identifier.scopusauthorid | Vanhoutte, PM=7202304247 | en_US |
dc.identifier.citeulike | 11777194 | - |
dc.identifier.issnl | 0163-7258 | - |